Business Wire

bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming Technology

The European Patent Office (EPO) upholds bit.bio's patent for its dual genomic safe harbour technology, opti-ox™, securing the broadest possible claims for programming of pluripotent stem cells (PSCs) ...
Business Wire

bit.bio introduces first product in groundbreaking ioCRISPR-Ready Cells™ product range, paving the way for new advances in disease modelling and drug discovery

CAMBRIDGE, England--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures, today announces the launch of the first offering from its new product range - ioCRISPR-Ready Cells™. This ...
News Medical

bit.bio launches new custom disease model cells offering, advancing disease research & drug discovery

The disease-relevant mutation is engineered into bit.bio’s human ioWild Type TM cells using CRISPR/Cas9 gene editing. As disease model cells come from an identical human genetic background to ioWild ...